Trials / Completed
CompletedNCT00293176
The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)
A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 821 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 45 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy and safety of donepezil in individuals with mild cognitive impairment on measures of cognition, global function and behavior.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Donepezil Hydrochloride | Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit. |
| DRUG | Placebo | Subjects will receive matching placebo tablets. |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2007-03-01
- Completion
- 2007-03-01
- First posted
- 2006-02-17
- Last updated
- 2011-04-01
Locations
54 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00293176. Inclusion in this directory is not an endorsement.